摘要
目的探讨晚期结直肠癌患者铂类药物化疗前后外周血切除修复交叉互补基因1(ERCC1)mRNA的表达及意义。方法采用RT-PCR分别检测98例晚期结直肠癌患者(结直肠癌组)含铂化疗方案化疗前后及94名健康对照志愿者(健康对照组)外周血ERCC1 mRNA表达水平。采用t检验比较结直肠癌组患者与健康对照组外周血ERCC1 mRNA表达水平差异;采用χ2检验比较ERCC1阴性患者与ERCC1阳性患者化疗有效率差异;采用t检验比较晚期结直肠癌患者化疗前后外周血ERCC1 mRNA表达水平差异、化疗有效与化疗无效晚期结直肠癌患者化疗前后外周血ERCC1mRNA表达水平差异。结果 (1)结直肠癌组患者化疗前ERCC1 mRNA表达水平为53.96±27.64,高于健康对照组的34.89±26.40,且差异有统计学意义(t=2.231,P<0.05)。(2)ERCC1阴性患者化疗有效率为57.9%(22/38),高于ERCC1阳性患者的28.3%(17/60),两者之间差异有统计学意义(χ2=4.435,P=0.035);(3)98例晚期结直肠癌患者化疗前后外周血ERCC1 mRNA表达水平分别为34.81±26.71、49.45±23.67,化疗后高于化疗前,且差异有统计学意义(t=2.343,P<0.05)。化疗有效患者与化疗无效患者化疗前外周血ERCC1 mRNA表达水平分别为34.01±27.54、35.16±26.94,差异无统计学意义;化疗后分别为40.04±25.93、56.57±28.75,差异有统计学意义(t=2.175,P<0.05);化疗无效患者化疗前后外周血ERCC1 mRNA表达水平差异有统计学意义(t=2.554,P<0.05),化疗有效患者化疗前后外周血ERCC1 mRNA表达水平差异无统计学意义。结论外周血ERCC1 mRNA表达水平可作为结直肠癌患者术后辅助化疗方案选择及预后判断指标。
Objective To explore the expression and its clinical significance of excision repair cross complementary gene 1 （ERCC1） mRNA before and after chemotherapy platinum in advanced colorectal cancer patients. Methods RT-PCR was used to detect the expression of ERCC1 mRNA of the peripheral bloods in 98 cases of colorectal cancer patients （colorectal cancer group） and 94 healthy controls volunteers （healthy control group）. The t test was adopted to compare peripheral blood ERCC1 mRNA expression level difference in colorectal cancer patients and healthy controls, Thex2 test was adopted to compare chemotherapy efficient difference in ERCC1 negative patients and ERCCI positive patients ;The t test was adopted to compare peripheral blood ERCC1 mRNA expression level difference in advanced colorectal cancer patients before and after chemotherapy, in chemotherapy and effective chemotherapy invalid advanced colorectal cancer patients before and after chemotherapy platinum. Results （1）The expression of ERCC1 mRNA was significantly higher in colorectal neoplasm 53.96 ± 27.64than that in the normal controls34.89 - 26.40, and the difference was statistically significant（t =2. 231 ,P 〈0.05）. （2） The response rate of the ERCC1 negative group was 57.9% （22/38）, that of the ERCC1 positive group was 28.3% （17/60）. There was significant correlation between the expression of ERCC1 and the efficacy of chemotherapy 0（2 =4. 435 ,P =0.035）. （3） The peripheral ERCC1 mRNA expression level of 98 cases of advanced colorectal cancer patients before and after chemotherapy was 34.81 ± 26.71,49.45 ± 23.67, higher after chemotherapy than betore chemotherapy, and the difference was statistically significant （ t = 2. 343, P 〈 0.05 ）. Effective chemotherapy patients and chemotherapy invalid patients before chemotherapy with peripheral ERCC1 mRNA expression level respectively 34.01±27.54, 35.16± 26.94, the difference had no sense of statistics; chemotherapy respectively after 40.04±25.93, 56.57± 28.75, difference was statistically significance（ t = 2. 175 ,P 〈 0.05 ） ; chemotherapy invalid patients before and after chemotherapy peripheral ERCC1 mRNA expression level difference had statistical significance （ t = 2. 554, P 〈 0.05 ） , effective chemotherapy patients before and after chemotherapy peripheral ERCC1 mRNA expression level difference was not statistically significant. Conclusion ERCC1 mRNA expression level might be useful in the choice of chemotherapy regimes and evaluation of prognosis for patients with colorectal cancer after surgery.
出处
《中华消化病与影像杂志（电子版）》
2012年第3期10-13,共4页
Chinese Journal of Digestion and Medical Imageology(Electronic Edition)
关键词
结直肠肿瘤
切除修复交叉互补基因1
抗肿瘤联合化疗方案
Colorectal neoplasms
Excision repair cross complementary gene 1
Antineoplastic combined chemotherapy protocols
